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Abstract
Proof of causality of most neuromental disorders (NMD’s) is largely unavailable. Lessons from four-decade investigations of
the epidemiology, immunology, pathogenesis, prevention and therapy of perinatal infectious agents, which invade directly the
nervous system, have led us to propose a new indirect effect hypothesis: maternal transplacentally-acquired antibodies, to
agentswith epitope molecular mimicry with the developing nervous system, can cross the fetus/infant’s blood–nervous system
barriers to cause NMD’s, clinically manifest years later.
Further rationale is provided by relevant evolutionary/developmental (EVO–DEVO) considerations—applicable also to
some vaccines. The hypothesis is being tested in: (a) older pregnancy studies with available maternal and newborn sera, and
follow-up of the progeny for NMD’s; and (b) NMD registry individuals linked to their stored newborn blood spots.
Preliminary results support a possible role for schizophrenia of high-tittered antibodies to some agents (toxoplasma, inﬂuenza
and herpes simplex type 2 virus).
A model that includes likely genetic and postnatal inﬂuences is schematized and a list of putative agents and factors, based
on varying rationales, is tabulated. In case pilot studies are conﬁrmed, the identiﬁed agent(s) and antibodies would need to be
tested in new prospectively enrolled pregnant women, so as to establish further risk factors leading to possible preventive
modalities.
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“Tracing the causes of mental illness is a much more
difﬁcult task than locating structural damage to the
brain” Eric R Kandel “In Search of Memory”
(2006)
Introduction
We were inspired to emulate the more personal
approach of Kandel’s personal journey of 50 years,
rather than with the more stereotyped approach to
writing scientiﬁc papers. Of particular relevance is
how Kandel’s initial interest in psychiatry led him,
after developing the neuroscience of memory in lower
biological forms, to return to issues about neuro-
mental processes in people.
Similarly, our early experience in clinical medicine,
epidemiology and immunology, with a focus particu-
larly on perinatal infections, has taken us—over the
past four decades—on a circuitous journey, to take on
new challenges related to the causality, diagnosis and
prevention of some neuromental disorders (NMD’s).
During our journey, we have also explored various
aspects of evolution (viruses, immunology and
sexually transmitted infections) and of development
(placenta and immune systems). Now that evolution
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discipline of EVO–DEVO, we convey much of
the information and rationale relevant to our
hypothesis within the broader EVO–DEVO perspec-
tive of Biology.
WehadbeenfamiliarwiththeNMD’sassociatedwith
many infectious agents acquired in utero,i n t r a p a r t u m
and during infancy, which—following HIV/AIDS
parlance, we will also consider altogether as perinatal
infections. Occasionally we would also be asked to
consult on psychiatric diseases presenting as infectious
diseases (Wurtz 1998). As we became more acquainted
with the many newer advances in neuroscience,
moleculargeneticsandpsychiatry(CharneyandNestler
2004),wewerestruckbythescarcityofprovencausality,
speciﬁc laboratory or radiological diagnostic tests and
preventiveapproachesforalargenumberofNMD’s.As
medical scientists also involved in the epidemiology of
global infectious diseases (Nahmias et al. 1990) we had
not been as aware of the enormityof the total burden of
NMD’s in the world. The World Health Report (2001)
estimated that NMD’s represented at least 12% of all
diseases, with around 10% occurring by the age of 12
years, and at least twice that many in adolescents and
adults. Quality-of-life and Disability Lost Years
(DALYs) measurements demonstrate the enormous
impact on afﬂicted individuals. Olness (2003), from a
more clinical perspective, has also conﬁrmed that the
effects on neural development leading to cognitive
impairment represents a worldwide epidemic. Assum-
ing that there is a no great variability among different
world populations (in case of schizophrenia the rate
globally is around 1%), since few causalities are known
or preventive measures available, one can estimate that
over10–20millionofthe.100millionbabiesbornthis
yeararedestinedtodeveloponeormoreNMD’sintheir
life. These numbers are higher than the estimates of the
globalimpactofthecombinednumberofchildrenborn
every year who will develop tuberculosis, malaria and
HIV, or of neonatal infections alone (Stoll 1997).
Itisnothardtopredictthatthelargeamountofbasic
neuroscience knowledge unraveled in 1990s “Decade
oftheBrain”andsincethen(Natureeds.2002;Kandel
2006), will result in many more novel treatments for
afﬂicted individuals, than in the development and
application of new preventive modalities. We base this
prediction on our experience of over 20 years with
HIV/AIDS (Schinazi and Nahmias 1988), which
provides a good infectious model of a chronic disease,
with similar attached stigmas as several NMD’s. More
than 20 antiretrovirals are now available for treatment
of the viral infection, whose most effective impact in
pediatrics has been in the primary type prevention of
maternal-child transmission. However, despite gener-
allygoodeffectivenessforthetreatmentofchildrenand
adults,thereisnocureyetoftheaffectedindividuals,as
is the case for manytherapies for NMD’s.Both disease
entities have common problems as to compliance, cost
and side effects, often associated with drug inter-
actions. There are also other similarities for both
entities: (a) drugs for treatment have generally been
poorly studied in children and pregnant women, in
whompossibleill-effectsontheprogenyareofconcern;
(b) there is a continuous need for an infrastructure of
health personnel, education, and counseling; and
(c) for both entities, even if it were possible to treat
every clinically affected individual, unless successful
prevention modalities are found and applied effec-
tively,morecasesneedingtherapieswillaccruetothose
alreadyon chronic treatments. One possible difference
is that, while there has been a great deal of HIV/AIDS
“activism”—helpingtoprovidethefundsandthedrugs
for treating individuals in developing countries
(unfortunately as yet, only for a small proportion),
there is no apparent comparable activism for drugs to
treat NMD’s.
Our hypothesis, whose speciﬁc aim is to ascertain
possible infectious agents that can be primarily
prevented, is ﬁrst provided as a general guide for the
reader in Figure 1. This simpliﬁed ﬁgure is made more
comprehensive in two later ﬁgures, comprising (a) a list
of putative infectious agents and factors to study, based
on preliminary results and (b) a model of the possible
multifactorial mechanistics operating in space and
time—in the nervous system and during, as well as
after, the perinatal period. Thus, rather than a direct
pathogenetic effect of infectious agents on the nervous
system of the fetus/infant, the hypothesis proposes an
indirect effect. In this case, it is the antibodies of the
mother to infectious agents, with molecular mimicry to
the developing nervous system, which are transferred
transplacentally, crossing the blood–nervous system
barriersmorepermissivelytocauseaproportionofsome
NMD’s of the fetus/infant that are most often not
clinicallymanifestuntillater years.Wenextpresenthow
this hypothesis was developed, as a longtime search for
“O” infectious agents. This more personal model,
(primarily by AJN,) will be followed by EVO–DEVO
considerations. Relevant information is also used to
identify putative causal infectious agents, vaccines, and
other pathogeneticfactors.Theclinico-epidemiological
and laboratory methods that can be used to test the
hypothesis, ﬁrst used by US and Danish colleagues, are
then presented with our own interpretation of the
related preliminary data. Finally, possible follow-up
studiesof anyconﬁrmedpilotstudiesaresuggestedthat
wouldhelptoevaluateapproachesforestablishingother
risk factors and possible preventive modalities, as
suggested from the success with the many perinatal
infections presented below.
Our longtime search for the “O” infectious
agents associated with neuromental disorders
We were ﬁrst introduced as long as four decades ago to
the NMDs associated with several infectious agents
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during infancy. Most of the bacterial causes of many
of these infections had been generally diagnosable, e.g.
neonatal bacterial meningitis, and some antibacterial
therapieshadbecomeavailable,preventingsome—but
by no means all—of the fatalities or neuromental
sequelae demonstrable later in life. The best success
achieved for over half a century relates to congenital
syphilis, whereby penicillin treatment of the mother
diagnosed before, or during, pregnancy prevented
fetuses and newborns from experiencing acute disease
manifestations, as well as the later sequelae detectable
sometimes decades later, e.g. neurosyphilis (Nahmias
et al. 1994a).
With the ability to grow viruses in culture, by the
1950s, and to diagnose some parasitic diseases in
research laboratories, neonatal sequelae were being
recognizedinindividuals,infectedprimarilyinutero,by
Toxoplasma, Cytomegalovirus and Rubella virus.
When, around the mid-1960s, one of us co-discovered
a new Herpes simplex virus (type 2), most frequently
transmitted intrapartum (Nahmias et al. 1970a), it
became apparent that its clinical manifestations,
includingcongenitalmalformationsand/orneuromen-
tal sequelae, often mimicked those of the other three
organisms and vice versa (Nahmias et al. 1970b;
Nahmias and Visintine 1979). To obtain more data of
medicalandpublichealthimportance,an alliance with
workers—at the time termed Communicable Disease
Center (CDC)—was formed to study all four agents
together, whenever one of the four was suspected
clinically. We eventually grouped these four perinatal
infectious agents into the acronym TORCH
(Nahmias et al. 1971), which has been widely used
since (Nahmias and Keyserling 1984). The “O” was
inserted presciently to convey the message that there
would likely be other perinatal agents with overlapping
symptomatologies, including NMD’s, yet to be
discovered. We put much effort, including attempts
todetectnewvirusesbyelectronmicroscopy(Leeetal.
1983), but failed ourselves to ﬁnd any “O” agents.
Other new agents, which arenotreadily diagnosable as
are bacteria, were indeed discovered by various
workers, including parvoviruses, hepatitis viruses and
HIV. However, of these, only perinatal HIV fulﬁlls the
requirement of an infection that can cause NMD’s
(Schinazi and Nahmias eds.1988).Based primarilyon
observations in animals or older-than-infant humans,
some investigators have implicated—without ﬁnite
proof— the role of Borna virus (Iwahashi et al. 1997),
humanendogenousretrovirusesHERV(Karlssonetal.
2001), and other infections (Shoenfeld and Rose eds.
2004),asdirectagentsor viaautoimmunemechanisms
intheetiologyofsomeNMD’s.IncaseofHIVperinatal
infection, we nowappreciate,not only the severeearly-
age encephalitis, but also the later neuromental
dysfunctions in HIV/AIDS children and adolescents,
even those receiving successful antiviral therapy
(Castellon et al. 2006). It should be emphasized that
thepathogenesisofneuralinvolvement,usingthemore
recentmolecular andcellular methods, are best known
for HIV, than for any of the TRCH agents.
The medical and public health focus on the TRCH
agentspossibly helpedintheimproveddevelopment of
speciﬁc, often rapid, diagnosis (Remington et al.
2006). Most important has been the advent of
successful approaches for the prevention of syphilis,
rubella, herpes simplex, HIV and toxoplasma—best
accomplished with the ﬁrst two types of preventive
modalities. These experiences provide models that
could be applied for the prevention of NMD’s
whatever the cause. Primary prevention is the most
Figure 1. A simpliﬁed version of the Gestational Neuro-Immunopathology (GENIP) Hypothesis, emphasizing that the NMD that might
occur (have its origin?) during neural development of the fetus/infant may not become clinically manifest until years or decades later.
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with general childhood vaccination (rubella), or by
diagnosingthematernalinfection,treatingthemother,
and/or performing a cesarean section (syphilis,
toxoplasma HSV, HIV and group B streptococcus).
Secondary prevention is accomplished by preventing an
established infection to go on to manifest diseases, by
effective treatment of the asymptomatically infected
infants, e.g. several bacterial infections. Tertiary
prevention attempts to stop the clinical manifestations
from progressing to more severe disease or death
(many of the above agents)
1. Primary or secondary
prevention of genetic causes, in our estimation, would
be even more of a problem than for a direct or indirect
infectious etiology, particularly as regards ethical and
socioeconomic considerations.
The speciﬁc diagnosis of the large majority of
NMD’s, except for those with single gene mutations
(e.g. fragile X syndrome, or a minority of cases of the
autism spectrum), is usually by combining symptoms
and/or sign as listed in DSM-IV-TR (2000). Infec-
tious disease specialists are more used to diseases,
which have known causes and speciﬁc diagnostic
methods, although having been plagued at times by
initial misinterpretation of the true causal agent, e.g.
Hemophilus inﬂuenzae, for decades supposed to be the
cause of inﬂuenza disease due to avirus. Frustrating to
many of us, currently, is the inability to ﬁnd a likely
infectious cause of a severe immunopathological
disease (Kawasaki) that may lead to coronary artery
complications, for which i.v. gammaglobulin serves as
a tertiary type of prevention.
Figure 2. A more detailed version of the GENIP Hypothesis, listing candidate infectious agents and vaccines, and pathways from mother to
fetus/infant, leading to NMD in later life. The rationale for selection of the candidate factors, detailed in the text, is based on molecular
mimicry, (and/or) their association with various NMD in newborns and older hosts.
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autoimmune, neuromental and other types of dis-
orders, a genetic predisposition is likely to be an
important factor. Although genetics or environmental
factors alone can cause a proportion of different
NMD’s, genetic and postnatal environmental inﬂu-
ences are likely to be contributory (Faraone et al.
1999), as noted later in our model. Most often,
postnatal environmental, including socioeconomic,
factors are considered, without inclusion of the
gestational
2 environment, during which a major
portion of neural development occurs. The neurode-
velopmental hypothesis had been earlier postulated by
Weinberger (1996) and Brown (1999). However, our
GENIP hypothesis also points to the importance of
researching, not only neural system genetics, but also
immuno-genetics, e.g. the genetically inﬂuenced
responsiveness of certain pre-pregnant or pregnant
women to produce high titers of IgG antibodies to
polysaccharide (PS) antigens.
A century of postmortem studies of the brain of
mentally ill persons has failed to reveal the clear,
localized lesions observed in such chronic diseases as
Huntington’s chorea, Parkinson’s disease or amyo-
trophic lateral sclerosis (Kandel 2006). Even in the
advent of newer means to detect anatomical and
functional abnormalities of the brain, e.g. functional
MRI, those methods have not yet allowed speciﬁc
diagnosis to be made. It is most often difﬁcult to
differentiate effects from causes. In contrast, studies of
the cerebrospinal ﬂuid (CSF), brain or other neural
tissues usually demonstrate direct or indirect markers
Figure 3. A model depicting the WINDOW for high or low levels of transplacentally-acquired IgG/antibodies to cause NMDs in relation to:
(1) development over time of neurological components and/or functions; (2) change over time in the permissiveness of Blood–Brain–CSF-
Barriers; and (3) a potential threshold for the development of dysfunction with time, dependent on genetic, epigenetic and postnatal
environmental inﬂuences.
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pathological markers is one of the main reasons why
we have sought possible indirect effects of infectious
agents, which may result from maternally-transmitted
transplacental antibodies. We have learned over the
years (Remington and Klein 2006) that, in case of
perinatal infections, readily discernable major brain
involvement (e.g. microcephaly with rubella and
cytomegalovirus; hydrocephalus with toxoplasmosis),
occur primarily during the ﬁrst 3–4 months of
gestation—a period also of great neurogenesis activity.
After 4 months gestation, despite the fact that a TRC
agent was still transmissible across the placenta until
delivery (sometimes even more readily transmitted as
with toxoplasma), the clinical effects are usually less
common or severe, with ocular or NMD’s clinically
manifest months or years after birth. We connected
these observations with the fact that, around 4 months
gestation is also the time when maternal antibodies
begin to be transmitted transplacentally.
There have been numerous reviews (Shoenfeld and
Rose 2004; Molina and Shoenfeld 2005)—as well as
the reports at the Lausanne Conference on the subject
in 2005, which have denoted a large number of
associations that have been made between infectious
agents or vaccines, and autoimmune diseases and/or
NMD’s. Despite considerable efforts, causality has
been extremely hard to prove. In case of acute
infections as suspect initiators, the best links are made
when the infection is clinically manifest, or when a
vaccine is administrated, and a NMD (or other ill-
effect) is observed within a month or at most two.
Side-effects of the new protein-conjugate meningo-
coccus PS vaccine, for instance, were mostly identiﬁed
prospectively for less than two months (MMWR
2006). In either case—infection or vaccine—the ill-
effects may be due to other coincidental causal stimuli
of the disease; this necessitates knowledge of the
regular incidence of the implicated disease entity in
similar populations and locations, as used for instance
by the Vaccine Safety Data Link (Chen et al. 1997). If
the infection or vaccine ill-effects are demonstrable
years later, or were due to epitope spreading or
polyclonal activation, the real culprit will most likely
be missed. Similarly, an association made on
epidemiological grounds without laboratory conﬁr-
mation may not detect the true causal factor, e.g. the
association made of a higher risk of schizophrenia in
babies born during the inﬂuenza season (Brown
1999), (see also results of Brown et al. (2004)
presented in Testability section.)
The two infectious agents most widely accepted as
causes of NMD’s happen to have ﬁrst been detected
within a period of a month, or so, after symptomatic
disease: (1) group A Streptococcus pyogenes infection,
e.g. tonsillitis or scarlet fever, with secondary Syden-
ham’s chorea and rheumatic heart disease; (2)
Campylobacter jejuni diarrhea,with the latermanifested
Guillain Barre ´ syndrome. Both entities have been
associated with molecular mimicry of sialic acids
common to those of the nervous system (Hughes et al.
1999; Kirvan et al. 2006). Together with the EVO–
DEVO considerations noted later, these data have
provided an important stimulus to focus on sialic acids
as a likely major “pathogenic epitopes”, for our
GENIP hypothesis (Figure 2).
Behavior is likely to be linked to our genes, as well as
environmental inﬂuences, including maternal alcohol
and drug abuse during pregnancy (Faraone et al.
1999; Drayna 2006) A genetic, particularly poly-
genetic, or epigenetic, causal association with any
NMD represents a major effort, despite the avail-
ability of a large number of new molecular genetic
tools. This has been exempliﬁed recently in case of
neuregulin 1 (NRG1)—a leading schizophrenia
susceptibility gene found by most, but not all
investigators, to be associated with this NMD
(Harrison and Law 2006). These authors note that
unequivocal proof of NRG1 as a schizophrenia gene
remains a daunting task, as several variants appear to
be non-coding, regulatory genes, which are likely to be
triggered by epigenetic or environmental factors.
An upset in the regulation of the gene could also
cause increased generation of a protein involved in
neuropathology (Law et al. 2006). The presence of
NRG1 in several organs, and its involvement in a
variety of developmental and other functions of
the nervous system (neuronal migration, synaptic
formation and glial differentiation among others) add
to problems of arriving at proof of causality.
Other considerations learned from our infectious
disease experience are: (1) a single agent may cause
different disease manifestations, e.g. pneumococcus
can cause otitis, sinusitis, meningitis, etc. Similarly,
the co-morbidity of more than one NMD in a single
individual’s life, whether at the same or different times
is not an uncommon clinical experience, and (2) the
disease may be caused by many infectious or non-
infectious agents, e.g. pneumonitis can be due to a
large number of different viral, bacterial, fungal or
parasitic infectious agents. It therefore would be
unlikely that any of the candidate infectious agents
whose rational for testing is described later, would
cause 100% of the NMD being investigated. Never-
theless, it would be most worthwhile to develop some
preventive measure for even a small proportion of any
severe, debilitating NMD, as was successfully accom-
plished for the NMD sequelae—including schizo-
phrenia cases—associated with prenatal rubella virus
(Brown et al. 2001).
An EVO–DEVO overview is particularly helpful to
bring together a variety of multifactorial aspects,
including relevant development and phylogenetic
aspects of the placenta and of the immune and
nervous systems. EVO–DEVO is also important as
related to the applicability of certain animal models to
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the differences in the placental anatomy and physi-
ology. The mental processes involving the brain cortex
are markedly different among lower species. Kandel
(2006), points out that studies in lower animals related
to cognitive functions are not as likely to prove as
helpful, as those related to emotional disorders, such
as anxiety problems or depression, or to memory
disorders related to the hippocampus. This is
attributed to cognition being associated with the
human cortex that developed over a recent brief
period of evolution, whereas emotion and memory are
associated with brain structures that have not
substantially changed, over long evolutionary periods,
between lower and higher species. Nevertheless, as
noted later, pathogenetic studies on the mouse cortex
have provided important means to relate certain genes
to the evolution of the human cortex (Hill and Walsh
2005; Walsh unpublished results 2006)
Evolutionary/developmental (EVO–DEVO)
perspective on relevant components of the
GENIP hypothesis
For those of us interested in the phylogeny and
development of the immune, nervous and reproduc-
tive systems, as well as of infectious agents, the linkage
of the two (EVO–DEVO) has proved both intellec-
tually rewarding and challenging. This new discipline
has been reviewed in a book by Carroll (2005), who
focused mainly on one of the major links between
evolution and development—the HOX genes, which
evolved over 640 million years ago, and have been
found to possess gene homologies between drosophila
ﬂies and higher species, including humans. At the
developmental level, HOX genes carry information
about how embryonic cells are arranged in space and
time, so that body cavities become organized, tissues
differentiated and organs formed, all in their proper
place and in proper sequences. The relative paucity of
the expected number of genes in humans, as
compared to the lower species—characterized in the
Human Genome Project—has led to the concept that
gene function is regulated by “switches”, as noted
decades earlier regarding the impact of the environ-
mental milieu on Escherichia coli mutants. Epigenetic,
as well as environmental factors, which can occur
during gestation or postnatally thus renders causality
much more complex to decipher than single gene
mutations—already quite a complex task.
EVO–DEVO aspects of the reproductive system,
including the placenta, remained obscure until HOX
genes were found to be involved (Lynch and Wagner
2006). Thus, HOX gene homologies have been
characterized in several of the reproductive organs in
amphibians, birds, monotremes, marsupials and
placental mammals. Novel HOX gene adaptations
over the past 3 million years have been involved
in fetal–placental–maternal immune interactions
permitting the fetus not to be rejected or to cause
harm to the mother. Such maternal–placental–fetus–
infant immune interactions we called the “Great
Balancing Act” (Nahmias and Kourtis 1997), as well
as factors related to why pregnant women do not reject
their fetus (Nahmias et al. 1998a), can be better
explained now in the context of the HOX gene
discoveries. Similarly, the embryology of congenital
anomalies of body patterning is now being better
understood (Goodman 2003).
Well appreciated, from the review in the book by
Benirschke et al. (2006) is the existence of a large
variety of anatomical and physical differences in the
placenta of different mammalian species—lending
again caution to which animal models to use.
Of particular relevance to our antibody focus, are
the marked differences in the selective transfer
of antibodies and their immunoglobulin (Ig) classes
in different species (Butler 2006). Thus, in humans,
transplacental transfer only occurs with the IgG class
and four subclasses (IgG1,2,3,4); the colostrum (and
breast milk), contains primarily IgA. In marked
contrast, IgG does not cross the placenta of horses,
pigs and cows, and is only found in the colostrum.
That the IgM class, in which many “natural” PS
antibodies to self are located, can be produced by the
fetus/infant—yet is unable to go across either the
placenta or the blood–nervous system barriers—
suggests that this immune system was adapted to
minimize the possible ill-effects of such IgM anti-
bodies on the nervous system.
In humans, relevant EVO–DEVO features are the
differences in the placental transmission of the four
IgG subclasses (Malek et al. 1996), and of the
antibodies to proteins or to PS (Nahmias and Kourtis
1997). Thus, antibodies to proteins, e.g. tetanus
toxoid are of almost equivalent titers in the newborn at
delivery to the mother’s. On the other hand, IgG2 and
antibodies to PS antibodies, e.g. to pneumococcus PS
(located primarily in IgG2), are about two-third of the
mother’s levels in the newborn at birth. A corollary is
that antibodies to proteins, being usually of higher
titers, will persist in the infant’s blood for up to 12–15
months, whereas the more commonly lower-tittered
antibodies to PS last about 6 months in the infant.
Awell-knownmodelforourGENIPhypothesisisthat
of blood group incompatibilities (Fagiolo and Toriani-
Terenzi2003),whichcanbebettercomprehendedfrom
an immunological EVO–DEVO viewpoint: (1)
Although less common population-wise, Rh incompat-
ibilityisamuchmoreseriousperinataldiseasethanABO
incompatibility, which tends to cause most frequently
no, or mild, disease—although severe hemolysis effects
canoccur.Asnotedabove,thisisdueinparttothemore
efﬁcienttransplacentaltransferofantibodiestoproteins
(Rh is a protein on the red blood cells), than PS anti-
bodies (A and B have PS on the RBCs). Furthermore,
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sensitized Rh-mother, if receiving RBC’s of a later
Rh þ fetus, will develop very high IgG anti-Rh
antibodies. In case of ABO incompatibility, the PS IgG
antibodies will tend to be low or absent, as the IgG
antibodies to PS antigens are not boostable. (2) The
ABObloodgroupincompatibilityisanexcellentmodel
for molecular mimicry (detailed later). The A þ fetus
will not produce anti-A antibodies (due to tolerance),
but acquires anti-B antibodies—initially in IgM byone
year of age and IgG by 2, or more years. This is due to
the molecular mimicryof the AB PS to those offoreign
E.colibacteria,withsimilar typesofmimicryoccurring
with other blood group antigens, e.g. the Lewis factor
and some bacteria. Of possible related interest is that
Insel et al. (2005) have reported that maternal fetal Rh
and ABO blood incompatibility was a risk factor for
schizophrenia, but only in male offspring.
Developmental aspects of the placenta, related to
monozygotic (MZ) and dizygotic (DZ) twins, impact
on the genetic interpretations of discordant results
found between MZ and DZ twins for studies on
NMD’s, as well as other entities. This is due to several
factors, including placental differences: the placentaof
MZ twins is most usually monochorionic, and that of
the DZ twins dichorionic (Benirschke et al. 2006).
Placental blood vessel anastomoses often occur in the
monochorionic placenta between twin A and twin B of
a MZ pair, causing, the well-known feto–fetal
transfusion syndrome or severe anemia in one of the
twins. However, it is not fully appreciated that other
proteins besides hemoglobin, that may affect one of
the two identical twins, have been found by Bryan
(1977) to differ in the newborn blood of MZ twins,
and not DZ twins. (We have recently initiated studies
in NMD discordant MZ and DZ twins, to expand
these unique old ﬁndings and to evaluate differences
in various antibodies and other factors—see Testabi-
lity section later).
Most studies on twins do not record placental
anatomy and pathology, as well as other non-genetic
factors, such as obstetric and newborn complications
that are more common in identical twins (Benirschke
et al. 2006). Seldom reported are also other such
possibly important variables as birth weight, gesta-
tional age, maternal or newborn infections,
and whether deliveries were vaginal or by cesarean
section. For instance, the initial data, suggestive of
the intrapartum route of maternal-child transmission
of HIV, was the ﬁnding of a greater infection
r a t ei nt h eﬁ r s tt w i nt h a ni nt h es e c o n dt w i n
(Palca 1991). Furthermore, our experience and that
of others (usually single case reports) indicate
that only one of the two MZ twins becomes infected
with a TRCH agent, or with HIV (Menez-Bautista
et al. 1986).
Results of twin studies and of family studies
generally tend to favor genetics and heredity
interpretations. For instance, in case of schizo-
phrenia, the overall ﬁnding has been that, when a
MZ twin has this serious NMD, the other identical
twin has a 50% risk; whereas among DZ twins, the
risk—when one is afﬂicted—is only 15% (Kandel
et al. 2000). This is interpreted usually as indicating
genetic inﬂuences, although placental and other
factors noted above may be involved. In addition, if
one looks at the other side of the coin, the ﬁnding
that 50% of MZ twins are not afﬂicted by
schizophrenia strongly support the likelihood of
non-genetic inﬂuences; when this is noted, mainly
postnatal environmental, including hormonal or
socioeconomic factors are usually considered.
Studies performed in family members, particularly
close relatives, who show a greater risk of a similar or
other, NMDs are often interpreted as providing
further evidence of genetics. However, familial is not
necessarily synonymous with hereditary (Torrey and
Yolken 2000). Long-term environmental factors such
as toxins, e.g. lead, in the household could be
involved. It is also well appreciated that the same
chronic infection, or one recurring, in a woman during
repeated pregnancies may affect more than one
sibling. For example, we have found cases in which
an HIV infected pregnant woman, who has experi-
enced ﬁve consecutive pregnancies, may only infect
two of the children with similar clinical manifes-
tations; without knowledge of the viral causation of
AIDS, genetic factors would likely be implicated.
Nevertheless, as infectious disease specialists, we are
convinced that genetic predispositions, whether
related to innate or adaptive immunity, are most likely
to play a role in deﬁning the range of subclinical, to
severe and fatal, disease with most infectious agents,
e.g. pneumococcus and poliovirus. Current single-
nucleotide polymorphism (SNP) studies should
provide further evidence of the genetics, and the
risk potential of particular infections, as is being
currently performed for NMD’s, cancer and other
disease entities.
The immunology of human infections with
relevance to what is now considered EVO–DEVO,
was reviewed over 20 years ago in two books we edited
(Nahmias and O’Reilly 1981,1982), as well as reports
on the ontogeny of immunity to some infectious
agents (Nahmias 1992; Nahmias et al. 1994b; 1998b).
With the discovery of TOLL receptors, found from
drosophila to humans, and the advances in molecular
genetics, much knowledge has been obtained of the
innate immune and the adaptive immune systems
(Flajnik and Du Pasquier 2004; Kasahara et al. 2004)
The interactions between the two types of immunity
had to adapt to each other as the host species
evolved—similar to the co-evolution of old families of
some viruses to their evolving host species (Nahmias
and Reanney 1977). Thus, as new immune cells and
systems developed in evolving hosts, the new ones
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more recent studies, for instance, suggests that the
protective immunity of PS antibodies developed early,
before the development of the classical T cell-MHC1
and 2-dependent production of antibodies to proteins.
Thus, we showed—at least in the mouse—that
antibody production to pneumococcus PS antigens
was CD1-dependent, and also required, as has also
been reported by other workers (Snapper et al. 2001),
a T cell which does not interact with characteristic
MHC1 or 2 (Kobrynski et al. 2005)
3.
Of relevant evolutionary interest, particularly
at the molecular level, is a whole issue of the
“Developmental and Comparative Immunology”
journal (Butler ed. 2006) on the antibody repertoire
from ﬁsh to man. In that same issue Marchalonis et al.
(2006) summarized antibody evolution as follows:
“Overall, antibodies of jawed vertebrates show
tremendous individual diversity, but are constructed
in incorporating design factors that arose with the
evolutionary emergence of the jawed vertebrates and
have been conserved through at least 450 million years
of evolutionary time”. These conclusions would
suggest that evolution had “all the time in the
world” to develop immune mechanisms that would
help to protect young children from severe, often fatal
diseases. Nevertheless, children below 2 years of
age cannot generally produce protective IgG anti-
bodies to PS-encapsulated bacteria such as H.
inﬂuenzae type B, pneumococci, meningococci, E.
coli K1, group B streptococci and tuberculosis
(disseminated disease).
Why then, are young children left vulnerable to
these virulent, often fatal or debilitating bacteria?
On the other hand, if infected in utero, at birth or soon
thereafter, the fetus/infant can produce all classes
of Ig, as well as antibodies to speciﬁc protein antigens
theyencounter.UsingELISPOTtechnology(Leeetal.
1991) we found that, even 6 months-gestation
live newborns can produce high numbers of IgG-,
IgM- and IgA-secreting cells and protein antibody-
secreting cells to syphilis (Stoll et al. 1993). ELISPOT
technology (Lee et al. 1989) measures the circulating
B cell components of the infant’s blood which are in
the process of producing Ig and antibodies. Serum
measurements are unreliable, as one cannot differen-
tiate newborn production of IgG, from maternal
transplacentally-acquired IgG; measurements of IgA
in serum also give false information on the infant’s
mucosal IgA production, as secretory IgA is broken
down in the liver (Nahmias et al. 1991).
From the concatenation of observations presented
above, we conclude, barring further data, that
mechanisms of both passive (transplacental acqui-
sition) and active IgG antibodies to PS antigens by the
fetus/young child—with no boostability—have been
adapted throughout evolution to protect our species
from the ill-effects of certain high-titered IgG
antibodies to PS, most probably due to their
molecular mimicry with those of the nervous system.
This interpretation is important also because of
possible correlates. One is that some caution should
be given to protein-conjugated PS vaccines, used so
successfully to decrease markedly H. inﬂuenzae type
B, pneumococcal and meningococcus C disseminated
diseases. Another advantage to these vaccines is that
the protection conveyed has also been shown to occur
not only in the vaccinated individuals, but also in non-
vaccinated persons, by epidemiological mechanisms
termed “herd immunity” (Musher 2006). We do not
wish to see further decreases in the availability and
research on vaccines, as reviewed by Klein and Helms
(2006). Production of conjugated vaccines varies from
that for the more traditional older vaccines—whether
inactivated or attenuated that were developed to
mimic, if not surpass, the immunity produced by
natural infection. However, the protein-conjugated PS
vaccines, and others planned for other bacteria
represent relatively novel approaches to the pro-
duction of vaccines, prepared to overcome what
appears to be evolutionarily developed immune
mechanisms. The concerns expressed with older
vaccines, e.g. measles, or those containing mercury,
in regards to autism, have not been validated. Even
though a small number of cases of Guillain Barre ´
syndrome have been recently associated with the new
protein-conjugate vaccine with four subgroups of
meningococci (A, C, Y and W135) (MMWR 2005,
2006), causality has not been proven conclusively.
This recent experience, however, suggests that follow-
ups of the newer vaccines be performed for longer
periods, and that animal models might prove useful.
Lambert, at the recent Lausanne conference (2005),
also raised the concern of administering vaccines to
adolescent girls, who might develop higher titered
antibodies (e.g to PS) than with natural infection by
the time they are pregnant any effect on their progeny
years after birth would be very hard to detect.
Molecular mimicry between infectious agents and
autoimmunity has been reviewed by Wraith, Goldman
and Lambert (2003), who have suggested that
regulatory factors to common T cell epitopes of
protein peptides would most likely be sufﬁcient to
prevent possible pathogenic effects. The various
aspects of molecular mimicry including vaccines,
have also been reviewed in the recent book by
Shoenfeld and Rose (2004) and an entire issue in
the journal Autoimmunity (Fujinami and Cunningham
eds. 2006). Some of the pathogenetic mechanisms
learned from autoimmunity studies are likely to
pertain to those associated to the GENIP hypothesis.
Thus, a mother could still produce high levels of
harmless antibodies towards her self, but, when these
are transplacentally transmitted to the baby, they
may still cause damage to the developing neural
systems. Of relevance here are cases of Guillain Barre ´
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condition herself during pregnancy (Buchwald et al.
1999; Sladky 2004; Buompadre et al. 2006). The
syndrome’s occurrence within families (Geleijns et al.
2004) is also of interest.
In view of EVO–DEVO and other considerations,
we have focused on PS, primarily sialic acids,
as potentially major “pathogenic epitopes”. We are
concentrating primarily on two types of molecules
containing such sialic acid epitopes that occur in
various parts of the nervous system, including the
brain. Both polysialic acid (PSA) and gangliosides
are found in large quantities in early fetal/infant
development and in smaller amounts in adults,
and both express molecular mimicry with some
infectious agents.
Polysialic acids are nine carbon molecules, linked
to each other at the a2–a8 position in chains of over
50 molecules (Chuong and Edelman 1984; Bruses
and Rutishauser 2001). Such PSA molecules are
associated with an important nervous system devel-
opmental protein—the neural cell adhesion molecule
(NCAM), important in a variety of neurological
functions in the brain and other parts of the nervous
system (Rutishauser 1996; Ni Dhuill et al. 1999).
Alterations in such molecules may cause ill-effects
during development of the various regions of the
nervous system (Cremer et al. 2000). PSA anti-
bodies, or enzymes that degrade PSA, when
administered to rodents, will cause several neural
dysfunctions (Arami et al. 1996; Rutishauser 1996;
Seki and Rutishauser 1998). The NCAM-associated
PSA is identical to the PSA in the capsule of two
clinically important infectious agents: (i) E. coli
K1
4—a major cause of neonatal meningitis and
septicemia (Glode et al. 1977; Frosch et al. 1985);
(ii) meningococcus B—a major cause of meningitis
and septicemia, but primarily in children and adults
(Finne et al. 1983). Patients with meningococcus B
infections have been found to produce antibodies to
NCAM (Nedelec et al. 1990). The molecular
mimicry, as demonstrated, for instance, with the
cross-reactivity between monoclonal antibodies to
the PSA of NCAM, E. coli K1 and meningococcus
B, has raised concern about including the meningo-
coccus B serogroup with the other four serogroups
(Pichichero et al. 2005) in the new protein-
conjugated PS meningococcus vaccine. Nevertheless,
Robbins’ group has proposed recently (Stein et al.
2006) that enough data are available to alleviate such
concerns—a position not shared by us, because the
data are insufﬁcient, particularly those they review in
humans.
The other sialic epitopes are those of gangliosides.
Gangliosides are ceramides with 1, 2, 3 or 4 sialic acid
epitopes (M, D, T and Q) and variable thin layer
chromatography mobility patterns (1,2,3,4—a or b)
e.g. GM1 or GQ4b (Rosenberg 1995). Gangliosides
are very common, and vary in type and quantity at
different stages of brain development in fetal brains of
different gestational periods, as well as brains of
different ages postnatally (Svennerholm et al. 1989).
Gangliosides are also found in other parts of the
nervous system, such as peripheral nerves and spinal
cord (Svennerholm et al. 1994). Theyalso occur in the
placenta, where they may have an immuno-modula-
tory role (Dyatlovitskaya et al. 1990).
A disease involving peripheral nerves—Guillain-
Barre ´ syndrome—has been associated with several
infectious agents (Ayala et al. 1999; Hughes et al.
1999; Ang et al. 2000; Nachamkin and Blaser eds.
2000; Press et al. 2001; Butzler 2004). Of these
associated agents, C. jejuni is the most widely accepted
as causal, inducing a neuro-immunopathological
disease through the molecular mimicry that exists
between its epitopes and those of the nervous system.
This very common bacterial diarrheal agent has been
found to contain, within its structure, several
gangliosides, e.g. GM1. Antibodies to such common
sialic acid epitopes can be induced by the bacteria and
cause several types of neural dysfunctions [cit. op
above]. Furthermore, antibodies to gangliosides have
been commonly found in the blood of patients with
GBS, although the agent itself cannot be cultured
from blood. A genetic predisposition is likely to play
an important role, as it is in case of several
autoimmune disorders (Shoenfeld and Rose eds.
2004), with several HLA class II alleles being involved
with C. jejuni (Rees et al. 1995).
C jejuni has been associated with about one third of
the total number of cases of Guillain Barre ´ syndrome
in several studies (Nachamkin and Blaser eds. 2000;
Vedeler 2000). It is also associated with an ocular
Miller Fisher syndrome with cerebellar involvement,
related most commonly to GQ4b antibodies (Rees
et al. 1995; Koga et al. 2001). Other agents that have
been associated with the Guillain Barre ´ syndrome,
albeit studied less well for causality are: Mycoplasma
pneumoniae, Hemophilus inﬂuenzae, cytomegalovirus
(CMV), Epstein-Barr virus (EBV), herpes simplex
virus (HSV) type 1, and varicella virus (as noted
earlier, also the swine inﬂuenza vaccine of the 1970s,
and the more recently used protein-conjugated PS,
four serogroup, meningococcus vaccine.)
One explanation for the possible involvement of
ganglioside molecular mimicry with viruses has been
suggested to be due to “self” ganglioside “pathogenic
epitopes” being picked up from host cell membranes
during viral replication, and inducing auto-antibodies
(Wraith et al. 2003). It is still not possible to rule out
that some infectious agents could induce epitope
spreading or a general polyactivation, which can be
associated more so with certain agents, e.g. Epstein-
Barr virus (Poole et al. 2006). It appears therefore
helpful to differentiate among different pathogenetic
mechanisms by concurrent testing of a variety of
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and inﬂammatory reactants in the same serum.
The oldest and best example of molecular mimicry,
associated with a neurological condition—Syden-
ham’s chorea, is that of group A streptococcus
(GAS). Recent studies indicate the pathogenesis is
related to a ganglioside GM1 (Kirvan et al. 2006). Of
interest are ﬁndings that the GAS pathogenesis related
to rheumatic heart disease, with M-protein molecular
mimicry, is likely to be due to T cell autoimmunity,
whereas that for the GAS-related NMD—Sydenham’s
chorea—is related to antibodies to common GAS
epitopes reacting mainly with the basal ganglia of the
brain (Guilherme et al. 2006; Kirvan et al. 2006).
Other possible GAS-related autoimmune conditions,
with causality less well ascertained, is the Pediatric
Autoimmune Neuropsychiatric disorders (PANDA)
associated with GAS, comprising a group of NMD’s
with different clinical manifestations (Swedo and
Grant 2005). Of some common interest is that
arthritis, a condition related to GAS, has been
associated with Campylobacter (Bremell et al.
1991), and that rheumatoid arthritis has been
associated with schizophrenia (Torrey and Yolken
2001).
There is some commonality between the most
accepted infectious agents with molecular mimicry to
the nervous tissue: C. jejuni and GAS. Both contain a
ganglioside (GM1), with production of anti-GM1
likely to be responsible for the neural immunopathol-
ogy. Yet the pathogenesis of the GM1 antibodies
appear to differ: (a) in relation to the Guillain Barre ´
syndrome, it appears to be due to complement-
mediated antibody cytotoxicity at motor nerve
terminals; (b) in relation to Sydenham’s chorea
the GM1 antibodies appear to affect the physiology
of the brain, disturbing primarily cell signaling
[cit op above].
It is difﬁcultto explain the differences in the effect of
the GM1 antibodies affecting peripheral nerves in one
case, and the brain in another. The differences may be
due to different effects or the permissiveness of the
various blood–nervous system barriers. Several recent
books have reviewed important aspects of blood-
neural system barriers (Nag 2003; Zheng and
Chodobski 2005). It appears that the blood–nervous
system barrier is more permissive to blood IgG
transfer than are the blood–brain barriers. The
blood–CSF barrier is also more permissive to IgG
and antibody transfer in fetal life and some time
postnatally (,1–2 years). Thus, CSF total protein is
known to be higher in the CSF of a premature 6
month gestation baby (up to 200 þ mg%), to
decrease to around 100mg% in a 9 month gestation
baby, and to reach adult levels of 20–40mg% around
1–2 years of age. Concurrently, measurements of IgG
blood:CSF ratios indicate approximately a similar
gradual fall of 100:1 in a 6 month gestational
premature infant to adult levels by 1–2 years of age;
similar ﬁndings have been noted with the passage of
IgG speciﬁc antibodies. Antibodies of high enough
titer would likely be transferred passively for a short
distance to the hippocampus or other brain areas
bathed by the CSF/ventricular ﬂuid. Several other
factors are known to increase the barrier permissive-
ness of hosts older than infants, including meningitis,
encephalitis or head trauma. One wonders whether
the trauma of a baby’s head passing through the birth
canal at delivery may not increase the permissiveness
of the blood–brain/CSF barriers, allowing the greater
passage of IgG antibodies to the newborn’s brain.
Information on the development of cell-to-cell
junction blood–brain barriers is difﬁcult to obtain in
human fetuses or infants. Active transport of different
molecules, including some drugs, occurs by this route
(Nag 2003). High levels of bilirubin, which occur with
Rh incompatibility, are known to be transferred across
this barrier, causing Kernicterus. It should also be
appreciated that any ill-effects caused by antibodies to
“pathogenic epitopes” would depend at what stage of
brain development particular gangliosides or PSA are
prevalent, and when particular processes or brain
components develop, e.g. neurogenesis develop earlier
than synaptogenesis, and the onset of development of
the hippocampus, the cerebellum and myelination
occurring after mid-gestation (Brody et al. 1987;
Kandel et al. 2000; Seress et al. 2001).
The patterning and plasticity of the neonatal cortex
is being pursued vigorously in more recent years
(Sur and Rubenstein 2005). New EVO–DEVO
insights are being obtained related to the evolution
and development of the human brain cortex by
Christopher Walsh’s group (Hill and Walsh 2005;
Walsh unpublished results 2006). Certain gene
products, found to be lower in association with
microcephaly in mice, were also observed to be in
lesser amounts in the brain of several lower species
than of humans, with the actual amounts correlating
with the evolutionary distance between the species
tested. Pursuit of such EVO–DEVO discoveries
should offer new windows of opportunity to study
the human cortex, likely to be relevant to causation of
NMD’s, as well as to their speciﬁc diagnosis,
prevention and treatment.
The rationale for testing particular infectious
agents, immune and inﬂammatory factors is partly
related to EVO-DEVO and other considerations
noted above, as well as results of preliminary studies
summarized below. The candidate infectious agents
are listed in Figure 2.
Testability of hypothesis
Testing the GENIP hypothesis requires obtaining
serum specimens during pregnancy and at delivery, as
well as in newborn infants at birth. The other
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which may take years or even decades to become
clinically manifest. Direct and indirect prospective
study approaches are available that can provide
possible populations of cases and matched controls
and the needed specimens to assay putative factors.
The small amount of sera available in some cases also
necessitates development and application of newer
technology. We owe a great debt of gratitude to
Danish, Swedish and US collaborating scientists of
different disciplines (whose names are listed in the
Acknowledgement section). These workers had
already identiﬁed the populations, some suspect
factors, and many of the laboratory test requirements.
In turn, our GENIP hypothesis has provided several
complementary aspects and concepts: the more likely
role of indirect rather than direct infectious neuro-
pathogenesis; the application of an EVO–DEVO
perspective, which led to the focus on PS sialic acids as
possible “pathogenic epitopes”; a greater list of
candidate infectious agents, as well as of other factors,
such as antibodies to PSA and Ig classes and
subclasses; the beneﬁt of studying MZ and DZ twins
with likely different placental transfer of IgG and
antibodies; vaccine implications; and other future
pursuits of preventive modalities. The preliminary
results summarized herein have been obtained mostly
by these collaborative scientists. (Interpretation of the
results is our own.) Our interactions have helped to
place their ﬁndings within the context of the more
permissive blood–nervous system barriers of the
fetus/infant, as well as develop a multifaceted, more
comprehensive model that places emphasis on time
and space.
Study populations
There are two “prospective” population study
approaches to test for antibodies to putative agents,
and correlative pathogenic immune and inﬂammatory
factors:
A. Direct type prospective study
Banked data and sera on pregnant women and
babies, with direct follow-up of the progeny to
ascertain particularly NMD’s have been used to
assay for suspect agents and factors. From 1959–
1966, the US National Institutes of Health
pioneered an approach enrolling women in early
pregnancy (primarily from New England and
California institutions). In this NIH Perinatal
Study, 54,000 live offspring were followed for up
to 7 years, primarily to study NMD. Sera had been
obtained during pregnancy and at delivery, as well as
from cord blood and placentas, and information on
obstetric and neonatal complications, twinning,
ethnic and other demographic features was obtained.
Several reports from the initial 7 year follow-up have
been published (e.g. Myrianthopoulos and Chung
1974). More recently, interest has been placed on re-
evaluating the behavioral disorders to test for
putative agents. With the support of the Stanley
Medical Research Institute, schizophrenia cases and
appropriate controls, matched for many factors, have
been followed in both New England and California,
30 or more years later (the results are discussed
below). Plans for enrolling 100,000 more US
pregnant women in 2006 to test for the causality
of several diseases, with onset in the perinatal
period, awaits funding. In the meantime, the Danish
Pregnancy Study (Olsen et al. 2001) was initiated
with 100,000 Danish pregnant women enrolled from
1998 to 2003, with their offspring being followed for
various diseases. Similar specimens, as the earlier
NIH study, are available for testing various factors of
interest in the blood of mothers and babies. Similar
type enrollments with lesser numbers have been, or
are planned to be, initiated in other countries.
B. More indirect prospective study—linking registries for
particular diseases with stored newborn screening blood
spots
Newborn blood spots to assay for a variety of genetic
and metabolic disorders have been used for several
decades in the US and various countries. Such blood
spots have been stored for many years, if not
decades, by only a few states, e.g. California in the
US, or countries, e.g. Denmark. An issue with blood
spots is that they can also be used for DNA
characterization, so that there are ethical and other
important considerations in regards their uses. For
instance, because their use for research was not
cleared by the public and proper governmental
agencies, testing the blood spots for research projects
is not permitted in Sweden.
The approach using the blood spots is to identify
individuals in a state or nation who have developed,
in later years, particular neuromental or other
disorders, often grouped within a registry of the
disease. The affected individuals and appropriate
matched controls are then linked to their stored
blood spots. The Danish State Serum Institute has a
bank of over 1 million stored blood spots, in whom
they performed, for instance toxoplasma IgM and
IgA antibody assays (Sorensen et al. 2002). Focus in
recent years in Denmark and California (with CDC)
has been placed on schizophrenia, autism and
cerebral palsy. We have also recently established a
collaboration with Danish and CDC scientists, using
a registry of MZ and DZ discordant twins with two
NMD’s, to study various IgG class and subclasses,
as well as several inﬂammatory factors and anti-
bodies to many of the candidate infectious agents, or
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Figure 2.
Laboratory assays
Assays have comprised more conventional ones
detecting and quantifying antibodies or Ig in serum
specimens, such as dye tests for toxoplasma IgG
antibodies or ELISA for HSV-2 antibodies. Because of
the small amount of blood in the newborn blood spots,
a technology that could assay for large numbers of
factors was needed. Danish workers used earlier an
immunoﬂuorescent technology for blood spots to test
for IgA and IgM antibodies to toxoplasma, indicating
fetal infection. Over the last few years, the Multiplex
Technology has become available (Earley et al. 2002).
This allows potentially testing up to 100 analytes
(such as antibodies, Ig, inﬂammatory or neurotropic
factors). It has been possible to extract enough sera
from one ﬁfth to one eighth of one of the three blood
spots, routinely obtained from babies soon after birth.
However, rigorous control is needed to ascertain that
there is no interference between reactants for each of
the analytes being tested. The usual procedure for any
Multiplex Assay(s) is to control concordance with
more standard serological means, and then test for
combinations (Earley et al. 2002). Multiplex appli-
cations to test several of the various putative infectious
agents or factors (listed in ﬁgure 2) have been
developed or are under development by collaborators
or other workers. They include Multiplex Assays for Ig
(Dasso et al. 2002), antibodies to PS antigens (Lal
et al. 2004), several cytokines (Kellar and Douglass
2003; Skogstrand et al. 2005), and neurotropic factors
associated with autism (Skogstrand et al. 2005;
Connolly et al. 2006). Attempts to develop Multiplex
assays for antibodies to gangliosides have so far been
unsuccessful and the testing of IgG antibodies to eight
gangliosides, (in sera obtained by Buka et al. (2001)
for schizophrenia and matched controls,) has yielded
negative results, using conventional serological tests
performed by the collaborating Swedish (Go ¨teborg)
laboratory.
Preliminary results
US NIH perinatal study
The ﬁrst results with the direct type prospective study
approach were published by Buka et al. (2001), who
identiﬁed 27 New England individuals with schizo-
phrenia and twice the number of matched controls.
Maternal sera at delivery were tested by ELISA for
antibodies to 6 infectious agents and to the three
major Ig classes. Statistically signiﬁcant differences
were found in sera obtained from mothers of babies
who developed schizophrenia, as compared to sera
from motherswhose progenyhad no NMD, in three of
the tests: Total IgG and IgM antibodies were higher in
the case group, which also had higher titers of
antibodies to herpes simplex virus type 2, than in the
matched controls (Table I). We tested later the same
sera, submitted blindly for testing of IgM antibodies
speciﬁc to HSV-2, and demonstrated very few positive
sera, whether in cases or controls. These results
suggest that primary infection, or reactivation of the
virus, in the mother did not occur close to the time of
delivery. A direct effect of herpes simplex virus type 2
on the brain appeared unlikely from our longtime
experience with neonatal herpes simplex virus infec-
tion (Nahmias 2004).
New York and California workers, using similar
procedures, followed up babies born in the US
Perinatal Study, identifying 60 cases of schizophrenia
and appropriate controls. These workers tested for
inﬂuenza virus antibodies, as inﬂuenza in pregnant
women had been implicated earlier in some, but not
all, reports (Brown et al. 2004). The workers found
Table I. Current results obtained in testing banked maternal sera or newborn blood spots–schizophrenia and matched controls.*
US-NIH perinatal study (maternal
sera at delivery)
Denmark (blood spots)
New England California
Cases vs. controls (n ¼ 27) (n ¼ 60) (n . 100)
1. Herpes simplex virus type 2 antibodies
Higher levels of total IgG ,0.05
Sero-positive for IgG antibodies NS
Positive for high levels of IgG antibodies ,0.05
Positive for IgM antibodies (few) NS
2. Inﬂuenza virus antibodies
Positive for high levels of inﬂuenza virus antibodies ,0.05
3. Toxoplasma antibodies
sero-positive for IgG antibodies NS NS
Positive for high levels of IgG antibodies NS ,0.05
Positive for IgM antibodies (few) NS ,0.05
*Statistical comparisons are between cases and matched controls without neuro-mental diseases (usually twice the number of cases).
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than controls. It should be noted that inﬂuenza, like
C. jejuni, is rarely found in the blood or brain, and that
studies in mice which showed behavioral problems
after inﬂuenza inoculation, also demonstrated no virus
in the brain (Shi et al. 2005). Thus, one explanation
for the mouse results is that the antibodies to the virus
themselves are responsible for the neural ﬁndings.
The results of IgG and IgM antibodies to
toxoplasma in the NIH and Danish studies are of
particular interest (Table I). In the California cohort,
higher titers of toxoplasma IgG antibodies were found
in the serum of mothers at delivery, whose pregnancy
went on to develop schizophrenia, than in matched
controls (Brown et al, 2005). Maternal serum IgM
antibodies were not statistically different, suggestive
that the maternal infection was not recent. Toxo-
plasma IgM antibodies were tested in newborn blood
spots linked to a large Danish Psychiatric Register,
which found signiﬁcantly more positive tests in cases
than controls (Norgaard-Pedersen B et al 2005). IgM
antibodies in neonatal blood is strong evidence of a
fetal infectious agent that has been able to cross the
placental barriers, but does not necessarily prove that
the test organism has also crossed the blood-neural
system barriers. Neuromental disorders, which are
manifest years or decades postnatally, of such
congenital infections as toxoplasma, rubella, syphilis
or cytomegalovirus, have been generally assumed to
be the result of the infectious agent remaining latent in
the nervous system. We would suggest that, while this
does occur, it may not always be the pathogenetic
mechanism. Maternal IgG antibodies (^fetally-
produced IgG antibodies to the agent’s proteins
[Stoll et al 1993]) are also quite likely to be involved.
The importance of the height of antibody levels and
not just seropositivity for three infectious agents, has
been helpful to validate our model (Figure 3), which
accounts for the importance of the blood brain/CSF
barriers. Depending on when the levels of transpla-
centally-acquired antibodies are at their highest, the
particular permissiveness in time of the blood–
brain/CSF/peripheral nerve barriers, and the coinci-
dence with the development of particular neural
processes and components, we conceive of a
“window” of optimal risk for pathological effects to
occur. Since most of the NMD’s occur years or
decades after any gestational immunopathological
insults, we have postulated also a threshold below
which clinical manifest disease will become apparent.
For instance, if girls generally are more likely to
develop higher thresholds than boys in earlier social
and language abilities (Baron-Cohen et al. 2005), they
may not be as suspectible to the loss of relevant
synapses during programmed pruning at 1-2 years of
age. Similarlythe synaptic pruning in adolescence may
explainthe clinical features ofschizophrenia becoming
ﬁrst manifest at that age (Feinberg 1982).
Conclusion
We have presented a hypothesis involving the indirect
effects of infectious agents as causes of a proportion of
some NMD’s. The rationale is based on our prior
experience with the more direct effects of infectious
agents on the fetus/infant, as well as on evolutionary-
developmental (EVO–DEVO) perspectives. Detailed
has been the testability of the hypothesis regarding
these study populations and laboratory methods
suggested by other workers. Based on preliminary
results using these methods and other considerations,
candidate infectious agents and factors, including
certain vaccines, have been identiﬁed for further
study (Figure 2). A new model portraying
the multifaceted factors that must be considered in
the hypothesis should assist ongoing and future
investigations (Figure 3).
We will end where we began...with the need to prove
causality and to develop speciﬁc diagnostic tests and
preventivemeasuresfor,inparticular,themoreclinically
serious and chronic of the NMD’s. Otherwise, the
millionsofbabiesborneveryyear,whowillbeaffectedby
oneormoreNMD’sduringtheirlifetime,aredestinedto
experience mild to severe debilitating chronic illnesses
for which treatment, even if available in developed
countries, would not be a satisfactory global option for
the future.
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Notes
1Although half a decade later, we unfortunately still have little to
offer with any of these three types of preventive modalities in the
case of congenital cytomegalovirus (CMV) infection.
2We have therefore used Gestational Neuro-Immunopathology, or
GENIP, to name our hypothesis.
3These observations suggest that the terminology used to
characterize antibody responses to PS antigens as “T cell-
independent” requires revision.
A. J. Nahmias et al. 1804K is German for capsule; K1 was the ﬁrst one identiﬁed possibly
because, among 100 or more capsular types of E. coli types, it
causes about three out of every four cases of E. coli newborn
meningitis or sepsis.
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